Soft Tissue Masses and Sarcoma Referral Pathway

Most soft tissue lumps are benign, but the clinical cost of missing sarcoma is high. The common error is not ignorance of sarcoma subtypes; it is treating an indeterminate lump as a harmless lump before appropriate imaging and referral.

Soft tissue sarcoma is uncommon compared with benign lipoma, cyst, haematoma and muscle injury. That rarity creates danger: a surgeon or general clinician may see many benign lumps for every sarcoma and become overconfident. The safer approach is to recognise behaviour that is not benign.

Soft tissue sarcomas arise from mesenchymal tissues such as muscle, fat, fibrous tissue, vessels, peripheral nerve sheath or undifferentiated soft tissue. The clinical pathway is similar across subtypes because the first decisions are anatomical and oncological: where is the mass, what does it involve, how should it be sampled, and can it be removed with a planned margin?

Important biological concepts:

• Pseudocapsule: many sarcomas compress adjacent tissue but are not truly encapsulated. Shelling out the mass leaves microscopic disease.
• Reactive zone: oedema, haematoma and post-biopsy change can contain tumour cells and may need inclusion in the resection field.
• Compartment anatomy: deep masses can involve muscle compartments, neurovascular bundles, periosteum, joint capsule or bone.
• Necrosis: large high-grade sarcomas may contain necrotic areas; biopsy should target viable enhancing tissue.
• Skip and metastatic risk: staging is subtype- and grade-dependent, but chest imaging is central for many extremity sarcomas because lung metastasis is common.

Classification in the initial clinic is not about memorising every histological subtype. It is about sorting the mass into a safe management pathway.

History

Ask precise questions that decide risk and pathway:

• When was the mass first noticed?
• Is it enlarging, stable or fluctuating?
• Was there real trauma, or did trauma simply draw attention to the mass?
• Is there pain, night pain, neurological symptom, vascular symptom or functional loss?
• Has it been aspirated, drained, injected or excised before?
• Is there a history of cancer, radiotherapy, genetic syndrome or immunosuppression?
• Are there systemic features such as weight loss, fever or multiple masses?

Examination

Examine the mass as a surgical field, not only as a lump.

Differential Diagnosis

Most masses are benign, but the role of the first clinician is to separate the confidently benign from the indeterminate. The table below contrasts the common benign mimics with the malignant lesions they hide, and the feature that should prompt imaging and referral.

Management is pathway-based. The most important decision is often what not to do: do not incise, drain, aspirate repeatedly or excise an indeterminate mass outside a sarcoma plan.

View larger

The referral pathway itself is well established, but several points remain debated and are favourite viva ground.

Soft tissue sarcoma is rare everywhere, which makes centralised, MDT-led care the single most consistent recommendation across regions. The framing below is global: regional guidance is cited as evidence contributing to one shared standard, not as country-specific practice.

Global Epidemiology

• Soft tissue sarcomas account for roughly 1% of adult malignancies and are far outnumbered by benign soft tissue lesions, which are at least 100 times more common.
• They can arise at any site; the extremities (especially the thigh) are the commonest location, followed by trunk and retroperitoneum.
• Incidence rises with age but the disease occurs across all age groups, and over 50 to 70 histological subtypes are recognised in the current WHO classification.
• Lung is the dominant site of distant metastasis for extremity sarcoma, which is why chest imaging anchors staging.

Side-by-Side Guideline Comparison

The recommendations converge: image before biopsy, biopsy before excision, and concentrate care in specialist units. Differences are mainly in wording of thresholds rather than principle.

Registries and Reference Data

• National sarcoma registries and reference networks (for example the UK BSG/National Cancer Registration data, the European EURACAN reference network and the US National Cancer Database) consistently show better margins, lower local recurrence and improved survival when patients are treated at high-volume centres.
• Reference-network data also document the persistent cost of unplanned excision, supporting the centralisation message rather than any single national policy.

High- versus Limited-Resource Practice

1. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20. doi:10.1186/s13569-016-0060-4.
2. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006.
3. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1982;64(8):1121-1127.
4. Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am. 1996;78(5):650-655.
5. Grimer RJ, Carter SR, Tillman RM, et al. Unplanned excision of soft tissue sarcoma. J Bone Joint Surg Br. 2001;83(2):203-206.
6. Venkatesan M, Richards CJ, McCulloch TA, Perks AGB, Raurell A, Ashford RU. Inadvertent surgical resection of soft tissue sarcomas. Eur J Surg Oncol. 2012;38(4):346-351. doi:10.1016/j.ejso.2011.12.011.
7. Toki S, Sone M, Yoshida A, et al. Image-guided core needle biopsy for musculoskeletal lesions. J Orthop Sci. 2022;27(2):448-455. doi:10.1016/j.jos.2020.12.017.